|
NL188581C
(nl)
*
|
1974-07-15 |
1992-08-03 |
Akzo Nv |
Werkwijze voor het bereiden van 11beta-hydroxy-18-alkylestraanverbindingen.
|
|
ZA763131B
(en)
*
|
1975-05-27 |
1978-01-25 |
Syntex Inc |
Use of flunisolide to treat respiratory diseases
|
|
SE8008524L
(sv)
*
|
1980-12-04 |
1982-06-05 |
Draco Ab |
4-pregnen-derivat, ett forfarande for deras framstellning, beredning och metod for behandling av inflammatoriska tillstand
|
|
IT1196142B
(it)
*
|
1984-06-11 |
1988-11-10 |
Sicor Spa |
Procedimento per la preparazione di 16,17-acetali di derivati pregnanici e nuovi composti ottenuti
|
|
SE8604059D0
(sv)
*
|
1986-09-25 |
1986-09-25 |
Astra Pharma Prod |
A method of controlling the epimeric distribution in the preparation of 16,17-acetals of pregnane derivatives
|
|
GR1001529B
(el)
*
|
1990-09-07 |
1994-03-31 |
Elmuquimica Farm Sl |
Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης.
|
|
SE9100341D0
(sv)
*
|
1991-02-04 |
1991-02-04 |
Astra Ab |
Novel steroids
|
|
DK0678097T3
(da)
*
|
1993-01-08 |
2000-02-07 |
Astra Ab |
Hidtil ukendte colon- eller ileumspecifikke steroidderivater
|
|
DE19635498A1
(de)
*
|
1996-09-03 |
1998-03-26 |
Byk Gulden Lomberg Chem Fab |
Verfahren zur Epimerenanreicherung
|
|
IT1291288B1
(it)
|
1997-04-30 |
1999-01-07 |
Farmabios Srl |
Processo per la preparazione di 16,17 acetali di derivati pregnanici con controllo della distribuzione epimerica al c-22.
|
|
US6266556B1
(en)
|
1998-04-27 |
2001-07-24 |
Beth Israel Deaconess Medical Center, Inc. |
Method and apparatus for recording an electroencephalogram during transcranial magnetic stimulation
|
|
IL144900A
(en)
|
2001-08-14 |
2013-12-31 |
Neurim Pharma 1991 |
Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs
|
|
US7825147B2
(en)
*
|
2003-08-29 |
2010-11-02 |
Ranbaxy Laboratories Limited |
Inhibitors of phosphodiesterase type-IV
|
|
WO2005051931A2
(en)
*
|
2003-11-26 |
2005-06-09 |
Ranbaxy Laboratories Limited |
Phosphodiesterase inhibitors
|
|
US7750151B2
(en)
|
2004-04-09 |
2010-07-06 |
Merck Sharp & Dohme Corp. |
Inhibitors of Akt activity
|
|
US8362075B2
(en)
|
2005-05-17 |
2013-01-29 |
Merck Sharp & Dohme Corp. |
Cyclohexyl sulphones for treatment of cancer
|
|
US7915286B2
(en)
|
2005-09-16 |
2011-03-29 |
Ranbaxy Laboratories Limited |
Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
|
|
EP1948164A1
(en)
|
2005-10-19 |
2008-07-30 |
Ranbaxy Laboratories, Ltd. |
Pharmaceutical compositions of muscarinic receptor antagonists
|
|
WO2007045980A1
(en)
*
|
2005-10-19 |
2007-04-26 |
Ranbaxy Laboratories Limited |
Compositions of phosphodiesterase type iv inhibitors
|
|
AU2007298549A1
(en)
*
|
2006-09-22 |
2008-03-27 |
Ranbaxy Laboratories Limited |
Inhibitors of phosphodiesterase type-IV
|
|
EP2066661A2
(en)
*
|
2006-09-22 |
2009-06-10 |
Ranbaxy Laboratories Limited |
Phosphodiesterase inhibitors
|
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
|
CN101674820B
(zh)
|
2006-12-26 |
2013-09-25 |
药品循环公司 |
在联合治疗中应用组蛋白脱乙酰酶抑制剂并监测生物标志物的方法
|
|
CA2674436C
(en)
|
2007-01-10 |
2012-07-17 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. |
Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
|
|
EP1958947A1
(en)
|
2007-02-15 |
2008-08-20 |
Ranbaxy Laboratories Limited |
Inhibitors of phosphodiesterase type 4
|
|
HRP20120361T1
(hr)
*
|
2007-03-14 |
2012-05-31 |
Ranbaxy Laboratories Limited |
DERIVATI PIRAZOLO[3,4-b]PIRIDINA KAO INHIBITORI FOSFODIESTERAZE
|
|
WO2008111009A1
(en)
*
|
2007-03-14 |
2008-09-18 |
Ranbaxy Laboratories Limited |
Pyrazolo [3, 4-b] pyridine derivatives as phosphodiesterase inhibitors
|
|
EP2170076B1
(en)
|
2007-06-27 |
2016-05-18 |
Merck Sharp & Dohme Corp. |
4-carboxybenzylamino derivatives as histone deacetylase inhibitors
|
|
ITMI20080645A1
(it)
|
2008-04-11 |
2009-10-12 |
Ind Chimica Srl |
Procedimento per la preparazione di budesonide
|
|
EP2111861A1
(en)
|
2008-04-21 |
2009-10-28 |
Ranbaxy Laboratories Limited |
Compositions of phosphodiesterase type IV inhibitors
|
|
GB0900484D0
(en)
|
2009-01-13 |
2009-02-11 |
Angeletti P Ist Richerche Bio |
Therapeutic agent
|
|
US8691825B2
(en)
|
2009-04-01 |
2014-04-08 |
Merck Sharp & Dohme Corp. |
Inhibitors of AKT activity
|
|
US8603521B2
(en)
|
2009-04-17 |
2013-12-10 |
Pharmacyclics, Inc. |
Formulations of histone deacetylase inhibitor and uses thereof
|
|
NZ598662A
(en)
*
|
2009-09-11 |
2014-03-28 |
Chiesi Farma Spa |
Pregnane derivatives condensed in the 16, 17 position with an n-substituted isoxazolidine ring as anti-inflammatory agents
|
|
GB0916608D0
(en)
|
2009-09-22 |
2009-11-04 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
|
US8859776B2
(en)
|
2009-10-14 |
2014-10-14 |
Merck Sharp & Dohme Corp. |
Substituted piperidines that increase p53 activity and the uses thereof
|
|
US9260417B2
(en)
|
2010-02-08 |
2016-02-16 |
Amitech Therapeutic Solutions, Inc. |
Therapeutic methods and compositions involving allosteric kinase inhibition
|
|
WO2011163330A1
(en)
|
2010-06-24 |
2011-12-29 |
Merck Sharp & Dohme Corp. |
Novel heterocyclic compounds as erk inhibitors
|
|
CA2805265A1
(en)
|
2010-08-02 |
2012-02-09 |
Merck Sharp & Dohme Corp. |
Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
|
|
HRP20191232T1
(hr)
|
2010-08-17 |
2019-11-01 |
Sirna Therapeutics Inc |
Inhibicija, posredovana rna interferencijom, ekspresije gena virusa hepatitisa b (hbv) korištenjem kratkih interferirajućih nukleinskih kiselina (sina)
|
|
EP2608669B1
(en)
|
2010-08-23 |
2016-06-22 |
Merck Sharp & Dohme Corp. |
NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
|
|
US8946216B2
(en)
|
2010-09-01 |
2015-02-03 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as ERK inhibitors
|
|
US9242981B2
(en)
|
2010-09-16 |
2016-01-26 |
Merck Sharp & Dohme Corp. |
Fused pyrazole derivatives as novel ERK inhibitors
|
|
DK2632472T3
(en)
|
2010-10-29 |
2018-03-19 |
Sirna Therapeutics Inc |
RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA)
|
|
EP2654748B1
(en)
|
2010-12-21 |
2016-07-27 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as erk inhibitors
|
|
AU2012245455A1
(en)
|
2011-04-21 |
2013-10-31 |
Merck Sharp & Dohme Corp. |
Insulin-Like Growth Factor-1 Receptor inhibitors
|
|
CA2845806C
(en)
|
2011-09-13 |
2019-06-11 |
Pharmacyclics, Inc. |
Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof
|
|
EP2770987B1
(en)
|
2011-10-27 |
2018-04-04 |
Merck Sharp & Dohme Corp. |
Novel compounds that are erk inhibitors
|
|
EP2844261B1
(en)
|
2012-05-02 |
2018-10-17 |
Sirna Therapeutics, Inc. |
SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
|
|
BR112015003729A2
(pt)
|
2012-08-24 |
2018-06-05 |
Univ Texas |
composto de fórmula estrutural i; composição farmacêutica; método de tratamento de uma doença mediada por caminho do hif; método de tratamento de uma doença causada por proliferação anormal de células; e método para alcançar um efeito em um paciente
|
|
US9155747B2
(en)
*
|
2012-09-13 |
2015-10-13 |
Chiesi Farmaceutici S.P.A. |
Isoxazolidine derivatives
|
|
JP6280554B2
(ja)
|
2012-09-28 |
2018-02-14 |
メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． |
Ｅｒｋ阻害剤である新規化合物
|
|
AU2013352568B2
(en)
|
2012-11-28 |
2019-09-19 |
Merck Sharp & Dohme Llc |
Compositions and methods for treating cancer
|
|
KR102196882B1
(ko)
|
2012-12-20 |
2020-12-30 |
머크 샤프 앤드 돔 코포레이션 |
Hdm2 억제제로서의 치환된 이미다조피리딘
|
|
US9540377B2
(en)
|
2013-01-30 |
2017-01-10 |
Merck Sharp & Dohme Corp. |
2,6,7,8 substituted purines as HDM2 inhibitors
|
|
US20160194368A1
(en)
|
2013-09-03 |
2016-07-07 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
|
EP3475275B1
(en)
|
2016-06-23 |
2024-04-10 |
Merck Sharp & Dohme LLC |
3-aryl and heteroaryl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors
|
|
US10975084B2
(en)
|
2016-10-12 |
2021-04-13 |
Merck Sharp & Dohme Corp. |
KDM5 inhibitors
|
|
US10711032B2
(en)
|
2016-11-08 |
2020-07-14 |
Regeneron Pharmaceuticals, Inc. |
Steroids and protein-conjugates thereof
|
|
WO2018213077A1
(en)
|
2017-05-18 |
2018-11-22 |
Regeneron Pharmaceuticals, Inc. |
Cyclodextrin protein drug conjugates
|
|
US12134631B2
(en)
|
2017-11-07 |
2024-11-05 |
Regeneron Pharmaceuticals, Inc. |
Hydrophilic linkers for antibody drug conjugates
|
|
WO2019094312A1
(en)
|
2017-11-08 |
2019-05-16 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
|
CA3086926A1
(en)
|
2018-01-08 |
2019-07-11 |
Regeneron Pharmaceuticals, Inc. |
Steroids and antibody-conjugates thereof
|
|
MX2020011546A
(es)
|
2018-05-09 |
2021-01-29 |
Regeneron Pharma |
Anticuerpos anti-msr1 y metodos de uso de los mismos.
|
|
EP3833668B1
(en)
|
2018-08-07 |
2025-03-19 |
Merck Sharp & Dohme LLC |
Prmt5 inhibitors
|
|
EP3833667B1
(en)
|
2018-08-07 |
2024-03-13 |
Merck Sharp & Dohme LLC |
Prmt5 inhibitors
|
|
CN112805006B
(zh)
|
2018-08-07 |
2024-09-24 |
默沙东有限责任公司 |
Prmt5抑制剂
|
|
WO2021126731A1
(en)
|
2019-12-17 |
2021-06-24 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
|
US20230108114A1
(en)
|
2019-12-17 |
2023-04-06 |
Merck Sharp & Dohme Llc |
Prmt5 inhibitors
|
|
US12441730B2
(en)
|
2019-12-17 |
2025-10-14 |
Merck Sharp & Dohme Llc |
PRMT5 inhibitors
|
|
AU2023336062A1
(en)
|
2022-09-02 |
2025-03-13 |
Merck Sharp & Dohme Llc |
Exatecan-derived topoisomerase-1 inhibitors pharmaceutical compositions, and uses thereof
|
|
CN120417935A
(zh)
|
2022-10-25 |
2025-08-01 |
默沙东有限责任公司 |
依喜替康衍生的adc接头-载荷及其药物组合物和用途
|
|
AU2023397331A1
(en)
|
2022-12-14 |
2025-06-26 |
Merck Sharp & Dohme Llc |
Auristatin linker-payloads, pharmaceutical compositions, and uses thereof
|